03 June 2021

Oxygen Plant-in-a-Box

The challenge, Access to oxygen can be the difference between life and death for patients with severe COVID-19. It is also a critical treatment for children with pneumonia, which remains the leading infectious killer of children under 5 years, claiming over 800,000 lives every year . The COVID-19 pandemic has turned an existing oxygen gap in many low- and middle…, The response ​, UNICEF worked with industry to rapidly develop an innovative emergency solution: the Oxygen Plant-in-a-Box. A fully functional Pressure Swing Absorption (PSA) oxygen plant, the package includes everything needed to produce large volumes of medical grade oxygen, including accessories supplied in the right quantities, installation of equipment, pre-…, 135, cylinders (20-litre bottles) can be filled in a 24-hour period. An icon of an oxygen plant, 720,000, litres of medical oxygen can be provided in a 24-hour period. An icon of a boy and a girl, 100, children with severe pneumonia or 50-60 COVID-19 patients can receive round the clock oxygen treatment at once. , The impact​, UNICEF worked with industry to take the package from idea to reality within just months. Now Oxygen Plant-in-a-Box packages are on their way to support countries as they respond to the ongoing pandemic.  This innovation will help save the lives of thousands of patients. With oxygen a critical treatment for COVID-19, as well as children with…, Resources, Stories and media coverage
07 December 2020

Resilient Oxygen Concentrators

The challenge, Every year,  over 7  million children  suffering from severe pneumonia in Low- and Middle-Income Countries (LMICs) urgently need oxygen to survive. This life-saving gas helps patients breathe when they cannot do so on their own – whether it is children with pneumonia or hypoxemia, newborns and mothers with birth complications, or patients with…, Every 43 seconds  , a child dies from pneumonia. Many of these deaths are preventable An icon of a boy and a girl, Over 7 million children, with severe pneumonia in low and middle-income countries need oxygen to survive each year  An icon of an oxygen concentrator, 15,000+ oxygen concentrators, were procured in 2020 as part of UNICEF’s COVID-19 response  , The response, UNICEF’s  Oxygen Concentrator Innovation Project  aims to develop a more durable, energy efficient, state-of-the-art oxygen concentrator to work in such challenging settings.    By working with innovators and health technology companies, UNICEF is driving the development and scale of a new concentrator with the following features:   Up to 60% more…, The impact, The project goal is to make oxygen available in primary healthcare facilities with power supply challenges, extreme climates and lack of maintenance expertise on site. UNICEF aims to fill the technology gap to ensure this life-saving gas can reach the 4.2 million children with severe pneumonia who require it to survive.   , Resources, Stories and Media Coverage
23 December 2015

Rethinking Amoxicillin Packaging

Pneumonia is the leading cause of under-five child mortality globally, accounting for an estimated 1.1 million child deaths each year (WHO, 2013). UNICEF’s innovation project sought to investigate how Amoxicillin could be packaged to match the recommended course of treatment and thus, simplify the administration of the antibiotics to children.…, THE PROBLEM, In 2011, WHO updated its recommendation for the treatment of pneumonia in community and replaced Co-trimoxazole with Amoxicillin (preferably in dispersible format) as the new first-line treatment for childhood pneumonia (WHO, 2011). Amoxicillin 250mg dispersible tablets (DT), scored is the most suitable format to treat childhood pneumonia in the…, INTRODUCING THE SOLUTION, The goal of this innovation project was to make Amoxicillin 250mg DT available in an innovative package that would simplify the administration of the right dosage of the antibiotics, and thereby ensure that low skilled community caregivers provide the right treatment to children suffering of pneumonia. An investigation was conducted to assess how…, CHALLENGES, The main challenges of the project were associated with the overall introduction of Amoxicillin DT 250mg into the national policies of countries. In terms of registration, many countries still listed Co-trimoxazole as their first-line of treatment for pneumonia in children under-five years of age. The adoption of Amoxicillin DT 250mg is…, THE PROCESS, The Amoxicillin DT 250mg package requirement was for a product package that supplied the dispersible tablets in such a way that it matched the treatment regimens for children of different ages and weights suffering of pneumonia. In 2012, UNICEF launched a request for Proposal (RFP) to supply Amoxicillin 250mg DT in order to increase supply to…, LESSONS LEARNED, The importance of understanding user behaviour during the development of a solution was emphasised during the course of the project, in particular because it operated in the area of medicines and antibiotics where compliance is important because improper medication may have negative consequences. High importance was therefore given to ensure that…, FOCUS ON THE FUTURE, This innovation is one solution in the battle against pneumonia. Other innovation projects will proceed to continue this fight. UNICEF is supporting an innovation for an appropriate pneumonia diagnostic aid device in resource-poor settings to improve accurate diagnoses and delivery of appropriate treatment[3].